KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (α-MSH). Research focuses on its anti-inflammatory properties in gastrointestinal, skin, and systemic inflammation models.
KPV binds intracellular targets and melanocortin receptors at low affinity, downregulating NF-κB and pro-inflammatory cytokine production. Evidence is strongest in IBD and colitis animal models.
Commonly reported research ranges: 500–1000 mcg daily (subcutaneous); oral protocols also used.
Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.
A widely used reconstitution for a 5 mg vial is 2 ml of bacteriostatic water. With a typical 500 mcg dose this works out to the unit count shown in the calculator below.
Approximately 1–2 hours.
This half-life informs how often KPV is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.
This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.
Lyophilized: refrigerated. Reconstituted: refrigerated, use within 28 days.
Not FDA approved. Research use only in the US.
For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.
Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.
See the app →KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (α-MSH). Research focuses on its anti-inflammatory properties in gastrointestinal, skin, and systemic inflammation models.
KPV binds intracellular targets and melanocortin receptors at low affinity, downregulating NF-κB and pro-inflammatory cytokine production. Evidence is strongest in IBD and colitis animal models.
Commonly reported ranges are 500–1000 mcg daily (subcutaneous); oral protocols also used. This is research information, not a recommendation — dosing should be individualized under clinical guidance.
Approximately 1–2 hours. This influences how often it is administered.
A common approach is to add 2 ml of bacteriostatic water to a 5 mg vial. Use the reconstitution calculator for exact unit counts.
Injection-site reactions; Limited human safety data; No well-characterized serious adverse events in published animal data.
Not FDA approved. Research use only in the US.
Registered or published clinical-trial sources for KPV are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.
Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.